Role of complement in motor neuron disease: animal models and therapeutic potential of complement inhibitors

Advances in Experimental Medicine and Biology

Volumn 632, Issue , 2008, Pages 143-158

  Woodruff, Trent M ^a   Costantini, Kerina J ^a   Taylor, Steve M ^a   Noakes, Peter G ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLUSTERIN; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT COMPONENT C5 INHIBITOR; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT FACTOR H; COMPLEMENT INHIBITOR; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTAMATE RECEPTOR ANTAGONIST; MESSENGER RNA; PMX 205; PMX 53; RECOMBINANT GROWTH FACTOR; RILUZOLE; UNCLASSIFIED DRUG; COMPLEMENT COMPONENT C5A; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; DRUG BINDING; ENTERITIS; EXPERIMENTAL MODEL; HUMAN; INNATE IMMUNITY; MOTOR NEURON DISEASE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; STEM CELL TRANSPLANTATION; TRANSGENIC MOUSE; ANIMAL; COMPLEMENT ACTIVATION; DISEASE MODEL; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; MOTONEURON; PATHOLOGY; RAT; SPINAL CORD; TRANSGENIC RAT;

ANIMALIA; MUS MUSCULUS; RATTUS; RODENTIA;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; COMPLEMENT ACTIVATION; COMPLEMENT C5A; DISEASE MODELS, ANIMAL; MOTOR NEURON DISEASE; MOTOR NEURONS; RATS; RATS, TRANSGENIC; RECEPTOR, ANAPHYLATOXIN C5A; RNA, MESSENGER; SPINAL CORD; SUPEROXIDE DISMUTASE;

EID: 58149349886     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-78952-1_11     Document Type: Review

References (76)

1. Abe, K., Aoki, M., Ikeda, M., Watanabe, M., Hirai, S. and Itoyama, Y. (1996) Clinical characteristics of familial amyotrophic lateral sclerosis with Cu/Zn superoxide dismutase gene mutations. J Neurol Sci, 136, 108-116
2. Andrews, J.M., Gardner, M.B., Wolfgram, F.J., Ellison, G.W., Porter, D.D. and Brandkamp, W.W. (1974) Studies on a murine form of spontaneous lower motor neuron degeneration - the wobbler (wa) mouse. Am J Pathol, 76, 63-78
3. Annunziata, P. and Volpi, N. (1985) High-levels of C3c in the cerebrospinal-fluid from amyotrophic lateral sclerosis patients. Acta Neurol Scand, 72, 61-64
4. Apostolski, S., Nikolic, J., Bugarski-Prokopljevic, C., Miletic, V., Pavlovic, S. and Filipovic, S. (1991) Serum and CSF immunological findings in ALS. Acta Neurol Scand, 83, 96-98
5. Arumugam, T.V., Shiels, I.A., Woodruff, T.M., Reid, R.C., Fairlie, D.P. and Taylor, S.M. (2002) Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine. J Surg Res, 103, 260-267
6. Arumugam, T.V., Shiels, I.A., Strachan, A.J., Abbenante, G., Fairlie, D.P. and Taylor, S.M. (2003) A small molecule C5a receptor antagonist protects kidneys from ischemia/ reperfusion injury in rats. Kidney Int, 63, 134-142
7. Arumugam, T.V., Woodruff, T.M., Stocks, S.Z., Proctor, L.M., Pollitt, S., Shiels, I.A., Reid, R.C., Fairlie, D.P. and Taylor, S.M. (2004) Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats. J Hepatol, 40, 934-941
8. Bao, L., Osawe, I., Puri, T., Lambris, J.D., Haas, M. and Quigg, R.J. (2005) C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol, 35, 2496-2506
9. Benatar, M. (2007) Lost in translation: Treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis, 26, 1-13
10. Boor, P., Konieczny, A., Villa, L., Schult, A.L., Bucher, E., Rong, S., Kunter, U., van Roeyen, C.R.C., Polakowski, T., Hawlisch, H., Hillebrandt, S., Lammert, F., Eitner, F., Floege, J. and Ostendorf, T. (2007) Complement C5 mediates experimental tubulointerstitial fibrosis. J Am Soc Nephrol, 18, 1508-1515
11. Brown, R.H., Jr. (1995) Amyotrophic lateral sclerosis: recent insights from genetics and transgenic mice. Cell, 80, 687-692
12. Chio, A., Benzi, G., Dossena, M., Mutani, R. and Mora, G. (2005) Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain, 128, 472-476
13. Clark, J.D., Qiao, Y.L., Li, X.Q., Shi, X.Y., Angst, M.S. and Yeomans, D.C. (2006) Blockade of the complement C5a receptor reduces incisional allodynia, edema, and cytokine expression. Anesthesiology, 104, 1274-1282
14. Cleveland, D.W. and Rothstein, J.D. (2001) From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci, 2, 806-819
15. Denny, K.J., Crane, J.W., Taylor, S.M. and Noakes, P.G. (2006) Differential localization and expression of complement in a rat model of motor neuron disease. Proc Aust Soc Biochem Mol Biol, 38, 58
16. Donnenfeld, H., Kascsak, R.J. and Bartfeld, H. (1984) Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J Neuroimmunol, 6, 51-57
17. Dupuis, L., di Scala, F., Rene, F., de Tapia, M., Oudart, H., Pradat, P.F., Meininger, V. and Loeffler, J.P. (2003) Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis. FASEB J, 17, 2091-2093
18. Ferraiuolo, L., Heath, P.R., Holden, H., Kasher, P., Kirby, J. and Shaw, P.J. (2007) Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. J Neurosci, 27, 9201-9219
19. Friedlander, R.M., Brown, R.H., Gagliardini, V., Wang, J. and Yuan, J. (1997) Inhibition of ICE slows ALS in mice. Nature, 388, 31
20. Garbuzova-Davis, S., Haller, E., Saporta, S., Kolomey, I., Nicosia, S.V. and Sanberg, P.R. (2007) Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res, 1157, 126-137
21. Gasque, P., Dean, Y.D., McGreal, E.P., VanBeek, J. and Morgan, B.P. (2000) Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology, 49, 171-186
22. Girardi, G., Berman, J., Redecha, P., Spruce, L., Thurman, J.M., Kraus, D., Hollmann, T.J., Casali, P., Caroll, M.C., Wetsel, R.A., Lambris, J.D., Holers, V.M. and Salmon, J.E. (2003) Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest, 112, 1644-1654
23. Girardi, G., Yarilin, D., Thurman, J.M., Holers, V.M. and Salmon, J.E. (2006) Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med, 203, 2165-2175
24. Goldknopf, I.L., Sheta, E.A., Bryson, J., Folsom, B., Wilson, C., Duty, J., Yen, A.A. and Appel, S.H. (2006) Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem Biophys Res Commun, 342, 1034-1039
25. Gong, Y.H., Parsadanian, A.S., Andreeva, A., Snider, W.D. and Elliott, J.L. (2000) Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration. J Neurosci, 20, 660-665
26. Grewal, R.P., Morgan, T.E. and Finch, C.E. (1999) C1qB and clusterin mRNA increase in association with neurodegeneration in sporadic amyotrophic lateral sclerosis. Neurosci Lett, 271, 65-67
27. Griffin, R.S., Costigan, M., Brenner, G.J., Ma, C.H.E., Scholz, J., Moss, A., Allchorne, A.J., Stahl, G.L. and Woolf, C.J. (2007) Complement induction in spinal cord microglia results in anaphylatoxin C5a-mediated pain hypersensitivity. J Neurosci, 27, 8699-8708
28. Groeneveld, G.J., Veldink, J.H., van der Tweel, I., Kalmijn, S., Beijer, C., de Visser, M., Wokke, J.H., Franssen, H. and van den Berg, L.H. (2003) A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol, 53, 437-445
29. Gurney, M.E., Pu, H., Chiu, A.Y., Dal Canto, M.C., Polchow, C.Y., Alexander, D.D., Caliendo, J., Hentati, A., Kwon, Y.W., Deng, H.X. and et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science, 264, 1772-1775
30. Harkin, D.W., Romaschin, A., Taylor, S.M., Rubin, B.B. and Lindsay, T.F. (2004) Complement C5a receptor antagonist attenuates multiple organ injury in a model of ruptured abdominal aortic aneurysm. J Vasc Surg, 39, 196-206
31. Hillebrandt, S., Wasmuth, H.E., Weiskirchen, R., Hellerbrand, C., Keppeler, H., Werth, A., Schirin-Sokhan, R., Wilkens, G., Geier, A., Lorenzen, J., Kohl, J., Gressner, A.M., Matern, S. and Lammert, F. (2005) Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet, 37, 835-843
32. Howland, D.S., Liu, J., She, Y.J., Goad, B., Maragakis, N.J., Kim, B., Erickson, J., Kulik, J., DeVito, L., Psaltis, G., DeGennaro, L.J., Cleveland, D.W. and Rothstein, J.D. (2002) Focal loss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc Natl Acad Sci U S A, 99, 1604-1609
33. Huber-Lang, M.S., Riedeman, N.C., Sarma, J.V., Younkin, E.M., McGuire, S.R., Laudes, I.J., Lu, K.T., Guo, R.F., Neff, T.A., Padgaonkar, V.A., Lambris, J.D., Spruce, L., Mastellos, D., Zetoune, F.S. and Ward, P.A. (2002) Protection of innate immunity by C5aR antagonist in septic mice. FASEB J, 16, 1567-1574
34. Jiang, Y.M., Yamamoto, M., Kobayashi, Y., Yoshihara, T., Liang, Y., Terao, S., Takeuchi, H., Ishigaki, S., Katsuno, M., Adachi, H., Niwa, J., Tanaka, F., Doyu, M., Yoshida, M., Hashizume, Y. and Sobue, G. (2005) Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann Neurol, 57, 236-251
35. Jonsson, P.A., Ernhill, K., Andersen, P.M., Bergemalm, D., Brannstrom, T., Gredal, O., Nilsson, P. and Marklund, S.L. (2004) Minute quantities of misfolded mutant superoxide dismutase-1 cause amyotrophic lateral sclerosis. Brain, 127, 73-88
36. Jonsson, P.A., Graffmo, K.S., Brannstrom, T., Nilsson, P., Andersen, P.M. and Marklund, S.L. (2006) Motor neuron disease in mice expressing the wild type-like D90A mutant superoxide dismutase-1. J Neuropathol Exp Neurol, 65, 1126-1136
37. Kawamata, T., Akiyama, H., Yamada, T. and McGeer, P.L. (1992) Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol, 140, 691-707
38. Klivenyi, P., Ferrante, R.J., Matthews, R.T., Bogdanov, M.B., Klein, A.M., Andreassen, O.A., Mueller, G., Wermer, M., Kaddurah-Daouk, R. and Beal, M.F. (1999) Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med, 5, 347-350
39. Krieger, C., Perry, T.L., Hansen, S. and Mitsumoto, H. (1991) The wobbler mouse: amino acid contents in brain and spinal cord. Brain Res, 551, 142-144
40. Lee, M.K., Borchelt, D.R., Wong, P.C., Sisodia, S.S. and Price, D.L. (1996) Transgenic models of neurodegenerative diseases. Curr Opin Neurobiol, 6, 651-660
41. Lobsiger, C.S., Boillee, S. and Cleveland, D.W. (2007) Toxicity from different SOD1 mutants dysregulates the complement system and the neuronal regenerative response in ALS motor neurons. Proc Natl Acad Sci U S A, 104, 7319-7326
42. Ludolph, A.C., Bendotti, C., Blaugrund, E., Hengerer, B., Loffler, J.P., Martin, J., Meininger, V., Meyer, T., Moussaoui, S., Robberecht, W., Scott, S., Silani, V. and Van Den Berg, L.H. (2007) Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop. Amyotroph Lateral Scler, 8, 217-223
43. Matsumoto, A., Okada, Y., Nakamichi, M., Nakamura, M., Toyama, Y., Sobue, G., Nagai, M., Aoki, M., Itoyama, Y. and Okano, H. (2006) Disease progression of human SOD1 (G93A) transgenic ALS model rats. J Neurosci Res, 83, 119-133
44. McGeer, P.L. and McGeer, E.G. (2002) Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve, 26, 459-470
45. Messer, A. and Flaherty, L. (1986) Autosomal dominance in a late-onset motor neuron disease in the mouse. J Neurogenet, 3, 345-355
46. Miller, R.G., Mitchell, J.D., Lyon, M. and Moore, D.H. (2007) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev Jan 24;(1):CD001447
47. Mitchell, J.D. and Borasio, G.D. (2007) Amyotrophic lateral sclerosis. Lancet, 369, 2031-2041
48. Mollnes, T.E. (2004) Therapeutic manipulation of the complement system. In: The Complement System: Novel Roles in Health and Disease, Szebeni, J. (ed.). Kluwer Academic Publishers, Boston, pp. 483-516
49. Moreau, C., Devos, D., Brunaud-Danel, V., Defebvre, L., Perez, T., Destee, A., Tonnel, A.B., Lassalle, P. and Just, N. (2005) Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology, 65, 1958-1960
50. Niebroj-Dobosz, I., Dziewulska, D. and Janik, P. (2006) Auto-antibodies against proteins of spinal cord cells in cerebrospinal fluid of patients with amyotrophic lateral sclerosis (ALS). Folia Neuropathol, 44, 191-196
51. Pardo, C.A., Rabin, B.A., Palmer, D.N. and Price, D.L. (1994) Accumulation of the adenosine triphosphate synthase subunit C in the mnd mutant mouse. A model for neuronal ceroid lipofuscinosis. Am J Pathol, 144, 829-835
52. Perrin, F.E., Boisset, G., Docquier, M., Schaad, O., Descombes, P. and Kato, A.C. (2005) No widespread induction of cell death genes occurs in pure motoneurons in an amyotrophic lateral sclerosis mouse model. Hum Mol Genet, 14, 3309-3320
53. Pramatarova, A., Laganiere, J., Roussel, J., Brisebois, K. and Rouleau, G.A. (2001) Neuronspecific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. J Neurosci, 21, 3369-3374
54. Reaume, A.G., Elliott, J.L., Hoffman, E.K., Kowall, N.W., Ferrante, R.J., Siwek, D.F., Wilcox, H.M., Flood, D.G., Beal, M.F., Brown, R.H., Jr., Scott, R.W. and Snider, W.D. (1996) Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet, 13, 43-47
55. Ripps, M.E., Huntley, G.W., Hof, P.R., Morrison, J.H. and Gordon, J.W. (1995) Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A, 92, 689-693
56. Schmalbruch, H., Jensen, H.J., Bjaerg, M., Kamieniecka, Z. and Kurland, L. (1991) A new mouse mutant with progressive motor neuronopathy. J Neuropathol Exp Neurol, 50, 192-204
57. Sewell, D.L., Nacewicz, B., Liu, F., Macvilay, S., Erdei, A., Lambris, J.D., Sandor, M. and Fabry, Z. (2004) Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. J Neuroimmunol, 155, 55-63
58. Shaw, B.F. and Valentine, J.S. (2007) How do ALS-associated mutations in superoxide dismutase 1 promote aggregation of the protein? Trends Biochem Sci, 32, 78-85
59. Spalloni, A., Albo, F., Ferrari, F., Mercuri, N., Bernardi, G., Zona, C. and Longone, P. (2004) Cu/Zn-superoxide dismutase (GLY93?ALA) mutation alters AMPA receptor subunit expression and function and potentiates kainate-mediated toxicity in motor neurons in culture. Neurobiol Dis, 15, 340-350
60. Strachan, A.J., Woodruff, T.M., Haaima, G., Fairlie, D.P. and Taylor, S.M. (2000) A new small molecule C5a receptor antagonist inhibits the reverse-passive Arthus reaction and endotoxic shock in rats. J Immunol, 164, 6560-6565
61. Strachan, A.J., Shiels, I.A., Reid, R.C., Fairlie, D.P. and Taylor, S.M. (2001) Inhibition of immune-complex mediated dermal inflammation in rats following either oral or topical administration of a small molecule C5a receptor antagonist. Br J Pharmacol, 134, 1778-1786
62. Tomiyama, M., Kannari, K., Nunomura, J., Oyama, Y., Takebe, K. and Matsunaga, M. (1994) Quantitative autoradiographic distribution of glutamate receptors in the cervical segment of the spinal cord of the wobbler mouse. Brain Res, 650, 353-357
63. Trbojevic-Cepe, M., Brinar, V., Pauro, M., Vogrinc, Z. and Stambuk, N. (1998) Cerebrospinal fluid complement activation in neurological diseases. J Neurol Sci, 154, 173-181
64. Tsuboi, Y. and Yamada, T. (1994) Increased concentration of C4d complement protein in CSF in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry, 57, 859-861
65. Valentine, J.S., Doucette, P.A. and Zittin Potter, S. (2005) Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu Rev Biochem, 74, 563-593
66. Wang, J., Xu, G., Slunt, H.H., Gonzales, V., Coonfield, M., Fromholt, D., Copeland, N.G., Jenkins, N.A., and Borchelt, D.R. (2005) Coincident thresholds of mutant protein for paralytic disease and protein aggregation caused by restrictively expressed superoxide dismutase cDNA. Neurobiol Dis, 20, 943-952
67. Whitaker, J.N., Sciabbarrasi, J., Engel, W.K., Warmolts, J.R. and Strober, W. (1973) Serum immunoglobulin and complement (C3) levels: a study in adults with idiopathic, chronic polyneuropathies and motor neuron diseases. Neurology, 23, 1164-1173
68. Wong, P.C., Pardo, C.A., Borchelt, D.R., Lee, M.K., Copeland, N.G., Jenkins, N.A., Sisodia, S.S., Cleveland, D.W. and Price, D.L. (1995) An adverse property of a familial ALSLinked SOD1 mutation causes motor-neuron disease characterized by vacuolar degeneration of mitochondria. Neuron, 14, 1105-1116
69. Woodruff, T.M. and Taylor, S.M. (2005) Promics Pty Ltd. Use of a C5a receptor inhibitor to treat neurological or neurodegenerative condition (e.g. Huntington's disease, spinocerebellar ataxia, dentatorubral pallidoluysian atrophy, ischemic damage, motor neuron disease) involving inflammation. International Patent: WO2005092366-A1
70. Woodruff, T.M., Strachan, A.J., Sanderson, S.D., Monk, P.N., Wong, A.K., Fairlie, D.P. and Taylor, S.M. (2001) Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes. Inflammation, 25, 171-177
71. Woodruff, T.M., Strachan, A.J., Dryburgh, N., Shiels, I.A., Reid, R.C., Fairlie, D.P. and Taylor, S.M. (2002) Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat. Arthritis Rheum, 46, 2476-2485
72. Woodruff, T.M., Arumugam, T.V., Shiels, I.A., Reid, R.C., Fairlie, D.P. and Taylor, S.M. (2003) A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease. J Immunol, 171, 5514-5520
73. Woodruff, T.M., Arumugam, T.V., Shiels, I.A., Reid, R.C., Fairlie, D.P. and Taylor, S.M. (2004) Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats. J Surg Res, 116, 81-90
74. Woodruff, T.M., Pollitt, S., Proctor, L.M., Stocks, S.Z., Manthey, H.D., Williams, H.M., Mahadevan, I.B., Shiels, I.A. and Taylor, S.M. (2005) Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. J Pharmacol Exp Ther, 314, 811-817
75. Woodruff, T.M., Crane, J.W., Proctor, L.M., Buller, K.M., Shek, A.B., de Vos, K., Pollitt, S., Williams, H.M., Shiels, I.A., Monk, P.N. and Taylor, S.M. (2006a) Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J, 20, 1407-1417
76. Woodruff, T.M., Proctor, L.M., Strachan, A.J. and Taylor, S.M. (2006b) Complement factor 5a as a therapeutic target. Drugs Future, 31, 325-334